胰激肽原酶联合黄芪治疗糖尿病肾病的临床观察

目的:观察胰激肽原酶联合黄芪治疗糖尿病肾病的疗效。方法:78例糖尿病肾病患者随机分为2组,对照组采用口服胰激肽原酶治疗,治疗组在对照组治疗基础上加用黄芪注射液,2组疗程均为4周。观察2组疗效及24h微量尿蛋白排泄率(UPE)、尿白蛋白(Alb)、尿球蛋白(β2-MG)、尿糖蛋白(THP)、血清肌酐(Scr)和尿素氮(BUN)等指标的变化。结果:治疗后各项观察指标均显著下降(P<0.01),治疗组UPE、Alb、β2-MG、THP下降更为明显。2组总有效率分别为87.2%、66.7%(P<0.05)。结论:胰激肽原酶联合黄芪治疗糖尿病肾病对减少蛋白尿漏出有较好疗效。

Kallidinogenase plus Radix Astragali for Diabetic Nephropathy:Observation of Curative Efficacy

OBJECTIVE：To observe the efficacy of Radix Astragali Injection in combination of Kallidinogenase for diabetic nephropathy.METHODS： A total of 78 patients with diabetic nephropathy were enrolled and randomly assigned to receive Kallidinogenase plus Radix Astragali Injection orally（trial group） or Kallidinogenase alone（control group） orally for 4wk.The main outcome measures were UPE, Alb, β2-MG, THP, Scr, BUN etc.RESULTS： After treatment, all the indexes were decreased significantly（P 〈 0.01）, much as in the levels of UPE, Alb, β2- MG and THP in the trial group.The effective rate for trial group vs.control group were 87.2% vs. 66.7% （P 〈 0.05） .CONCLUSION ： Radix Astragali Injection in combination of Kallidinogenase could effectively reduce the excretion of urinary protein in patients with diabetic nephropathy.